awmsg logo



eslicarbazepine acetate (Zebinix®)


Reference No. 1214


Appraisal information

eslicarbazepine acetate (Zebinix®) 800 mg tablet
eslicarbazepine acetate (Zebinix®) 200 mg tablet
eslicarbazepine acetate (Zebinix®) 50 mg/ml oral suspension


Company: Eisai Ltd
BNF category: Central nervous system
NMG meeting date: 08/05/2019
AWMSG meeting date: 19/06/2019
   
   
Submission Type: Limited Submission
Status: In progress
Advice No: Not available
Ratification by Welsh Government: Not available

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

Indication

Adjunctive therapy in adolescents and children aged above 6 years, with partial-onset seizures with or without secondary generalisation. Eslicarbazepine acetate (Zebinix®) should be restricted to treatment of highly refractory patients who remain uncontrolled with, or are intolerant to, other anti-epileptic medicine combinations
Preliminary Appraisal Recommendation (PAR)
Download
Company Response to the Preliminary Appraisal Recommendation (CR PAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download